Results 271 to 280 of about 69,773 (297)

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

European Journal of Cancer, 2012
Lu Si, Yan Kong, Xinan Sheng
exaly  

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

Pigment Cell and Melanoma Research, 2011
Rory Wolfe, Alexander Dobrovic, Grant A Mcarthur   +2 more
exaly  

NRA

2012
openaire   +1 more source

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

European Journal of Cancer, 2018
Michael Constantin Kirchberger, S Ugurel, Thomas Eigentler   +2 more
exaly  

The NRA:

2019
openaire   +1 more source

Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer

International Journal of Cancer, 2015
Marta Schirripa, Chiara Cremolini, Fotios Loupakis   +2 more
exaly  

NRAS mutation status is an independent prognostic factor in metastatic melanoma

Cancer, 2012
Richard W Joseph, Jeff Gershenwald, Kevin B Kim   +2 more
exaly  

NRAS Gene Amplification

2020
openaire   +1 more source

Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor

European Journal of Cancer, 2018
Tianxiao Xu, Xue Bai, Jie Dai
exaly  

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

Pigment Cell and Melanoma Research, 2018
Alain P Algazi, Rosaura Esteve-Puig, Adil I Daud   +2 more
exaly